• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 5, 2014

View Archived Issues

Pharma: Other news to note

Allergan Inc., of Irvine, Calif., said UK regulators approved Botox (botulinum toxin type A) for the treatment of ankle disability due to lower limb spasticity associated with stroke in adults. Read More

Other news to note

Domain Therapeutics SA, of Strasbourg, France, and Xoma Corp., of Berkeley, Calif., entered a multistep collaboration involving Xoma’s research on allosteric modulation and Domain’s Dtect-All, a platform that has discovered small-molecule allosteric modulators for a wide range of G protein-coupled receptors (GPCRs). Read More

Clinic roundup

Hemispherx Biopharma Inc., of Philadelphia, presented a summary of the results of its Phase I/II study at the American Society for Microbiology Biodefense Conference in Washington, showing that when Flumist, a seasonal influenza vaccine, was administered intranasally in conjunction with the company’s Ampligen, a Toll-like receptor 3 agonist, 92 percent of subjects elaborated specific IgA antibodies against at least one of the homologous seasonal vaccine strains. Read More

Stock Movers

Read More

Financings Roundup

Auspex Pharmaceuticals Inc., of La Jolla, Calif., raised the proposed deal size of its initial public offering. The company plans to raise $66 million by offering 6 million shares in a range of $10 to $12, up from 5.5 million shares at the same range. Read More

Pharmacovigilance enters the FTC biosimilar debate

Seeing the biosimilar debate as a way to improve pharmacovigilance for all biologics, several biosimilar makers are now pushing for state notification regulations that would lead to transparent and more accurate patient health records. Read More

Molmed: Leukemia gene therapy filing imminent

Bidding to become the second European company to secure regulatory approval for gene therapy, Molmed SpA plans to seek a conditional marketing authorization in Europe for its genetically engineered cell therapy TK treatment for high-risk acute leukemia patients in the current quarter. Read More

Spinifex seeks funding to advance neuropathic pain drug to phase IIb

LONDON – Spinifex Pharmaceuticals announced the publication of positive Phase IIa data for EMA401, a first-in-class oral treatment for chronic neuropathic pain, and said it is now in the process of raising $40 million to $50 million to fund a broad Phase IIb program. Read More

NIH, biopharma enter new public-private partnership

In his typical self-effacing manner, National Institutes of Health (NIH) director Francis Collins poked fun at his own “acronym acrobatics” when introducing the Accelerating Medicines Partnership (AMP) to reporters in Washington on Tuesday. “We’re amped up,” he joked, “and we want to amplify for you why we are so excited!” Read More

Super ‘bowel’ score: Furiex riding high after phase III victory with eluxadoline

Furiex Pharmaceuticals Inc.’s Phase III win with lead compound eluxadoline in diarrhea-predominant irritable bowel syndrome (IBS-D) turned investors’ eyes to next moves, including a potential partner for the locally acting mu opioid receptor agonist and delta opioid receptor antagonist or a possible buyout, given the success earlier of its approved diabetes therapy Nesina (alogliptin benzoate). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Kymera’s phase I data lead big week for STAT6 space

    BioWorld
    It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe